<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by DigitalPharma2.0 on Medium]]></title>
        <description><![CDATA[Stories by DigitalPharma2.0 on Medium]]></description>
        <link>https://medium.com/@DigitalPharma2?source=rss-88a09b2175ab------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*gxBd6sJoUdLq9zGg.jpg</url>
            <title>Stories by DigitalPharma2.0 on Medium</title>
            <link>https://medium.com/@DigitalPharma2?source=rss-88a09b2175ab------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 14:56:29 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@DigitalPharma2/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Lack of reimbursement will limit the impact of digital therapeutics in global healthcare market]]></title>
            <link>https://medium.com/@DigitalPharma2/lack-of-reimbursement-will-limit-the-impact-of-digital-therapeutics-in-global-healthcare-market-b40615ba243d?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/b40615ba243d</guid>
            <category><![CDATA[dtx]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 18:13:39 GMT</pubDate>
            <atom:updated>2019-06-30T18:13:39.611Z</atom:updated>
            <content:encoded><![CDATA[<p>from <a href="https://www.globaldata.com/lack-of-reimbursement-will-limit-the-impact-of-digital-therapeutics-in-global-healthcare-market/">https://www.globaldata.com/lack-of-reimbursement-will-limit-the-impact-of-digital-therapeutics-in-global-healthcare-market/</a> <br>posted 25 Jun 2019</p><p>A major barrier to the widespread use of digital therapeutics (DTx) is the limitation or lack of reimbursement by public and private health insurance providers, says GlobalData, a leading data and analytics company.</p><p>Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are driven by high quality software programs to prevent, manage or treat a medical disorder or disease. They are used independently or with medications, devices, or other therapies to optimize patient care and health outcomes.”</p><p>Alessio Brunello, Pharma Analyst at GlobalData, comments, “Due to increasing levels in healthcare spending combined with declining R&amp;D returns, DTx represents a new way of treatment for Pharma companies in which regulatory approved digital systems are used to treat medical conditions as prescribed therapeutic interventions.”</p><p>GlobalData’s latest report, ‘<a href="https://www.globaldata.com/store/report/gdhcht025--digital-therapeutics-and-their-impact-on-healthcare/?utm_source=mediacentre&amp;utm_medium=pr&amp;utm_campaign=190625a_gd_ph_pr_digital_therapeutics_healthcare&amp;utm_nooveride=1">Digital Therapeutics and Their Impact on Healthcare</a>’ reveals that there is an unmet need for patient-centered care and DTx implementation is designed to fill that need to deliver reliable, evidenced-based interventions with a high control of the quality of personalized care based on individual patients’ needs. Moreover, DTx have the opportunity to speed up clinical trials and create a more fit for purpose approach through improved recruitment and retention of patients.</p><p>Brunello continues, “The industry’s interest in value-based care and patient centricity is helping drive the adoption of DTx as insurers and payers can use data and analytics to manage healthcare costs and help patients to receive appropriate treatment. This will drive the adoption of DTx as healthcare stakeholders are placing increasing emphasis on cost-effectiveness.”</p><p>DTx can be used to prevent, manage, or treat diseases across diverse indications, particularly chronic conditions, such as diabetes, respiratory diseases, and mental health conditions and neurological disorders. They are prescribed as monotherapy (standalone) or together with other therapies (adjunctive or add-on) or devices to optimize health outcomes.</p><p>Brunello adds, “Despite DTx technologies potentially reducing total health care costs, increasing trial efficacy and improving patients’ health, there are a few challenges to address before they become an integral part of modern medicine, such as better alignment between providers, pharmaceutical companies and payers.”</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b40615ba243d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Should Pharma Care About Digital Therapeutics?]]></title>
            <link>https://medium.com/@DigitalPharma2/should-pharma-care-about-digital-therapeutics-fafc29083f8d?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/fafc29083f8d</guid>
            <category><![CDATA[pharma]]></category>
            <category><![CDATA[dtx]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 17:53:35 GMT</pubDate>
            <atom:updated>2019-06-30T17:53:35.339Z</atom:updated>
            <content:encoded><![CDATA[<p>from <a href="https://www.lifescienceleader.com/doc/should-pharma-care-about-digital-therapeutics-0001">https://www.lifescienceleader.com/doc/should-pharma-care-about-digital-therapeutics-0001</a></p><p>Source: Life Science Leader<br>By <a href="https://www.lifescienceleader.com/author/rob-wright">Rob Wright</a>, Chief Editor, Life Science Leader<br>Follow Him On Twitter <a href="https://twitter.com/RfwrightLSL">@RfwrightLSL</a></p><p><strong>$1.7 billion.</strong></p><p>That was the entire digital therapeutics market in 2017. While that’s a little more than most people have in the bank, it’s still a fairly small number for most Big Pharmas. But that market is projected to grow at rate of 20.5 percent through 2025, which will make it nearly $8 billion. And yet, that’s not even half what AbbVie brought in last year — from just one product (i.e., 2018 sales of Humira equaled $19 billion)!</p><p>So, why should pharma care about <strong>digital therapeutics</strong>? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit. Hailing from Akili Interactive Labs, Applied VR, Dthera Sciences, Novartis, Otsuka, and Pear Therapeutics, their collective backgrounds are impressive (i.e., physicians and Ph.D.s) with diverse experiences that include biotech, clinical research, FDA, and pharma (i.e., big, rare disease, small, and specialty). Just as impressive are some of the therapeutic areas in which they are working to find (or have found) digital treatments, either as mono or adjunctive therapies (see Table 1).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/583/0*PlztE-HX0IdvKQW_.jpg" /></figure><p><strong>WHAT IS A DIGITAL THERAPEUTIC?</strong></p><p>Before we tackle whether pharma should care, let’s first define what a digital therapeutic is. “Part of the reason ‘digital therapeutic’ even became a term is that digital health got co-opted by medical records,” stated Edward Cox, CEO of Dthera Sciences. When you say digital health, people tend to think about electronic health records (EHRs). But implementation of EHR isn’t digital health; it’s the digitization of a sector. As a result, digital therapeutics began to be used as a catch-all for lots of digital technologies that drive therapeutic outcomes. “I can think of various companies that probably all have a pretty good claim to be a digital therapeutic, but their products range from things that look like drugs, to medical devices, diagnostics, consumer health, or even hospital services,” he added. But such an all-encompassing approach feels too broad. One panelist defined what his company does with digital therapeutics as the development of “prescription video games.” Such a simplistic definition seems fairly narrow, especially when you consider Otsuka and Proteus Digital Health, which gained FDA approval in 2017 for ABILIFY MYCITE, a drug-device combination product composed of oral aripiprazole tablets embedded with an ingestible event marker sensor that also includes a patch (wearable sensor), a smartphone application, and web-based portals for healthcare providers and caregivers. To reduce confusion, let’s turn to the formal definition published by the Digital Therapeutics Alliance (DTA) in October 2018.</p><p>Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.</p><p><strong>SO WHY SHOULD PHARMA CARE ABOUT DIGITAL THERAPEUTICS?</strong></p><p>This question was posed to each panelist. The first responded by noting how the pharma landscape has evolved from only small molecule to large molecule, and many modalities in between. “It always has been hard to deliver good therapy, but doing so digitally wasn’t possible 30 years ago,” he stated. But today it is part of the puzzle needed for better patient care, and if pharma doesn’t care, they’re missing out. Another panelist added, “You’ve probably heard the expression, ‘people don’t buy drills, they buy a hole in the wall.’ Whether our customers are payers, providers, or patients, they don’t buy drugs, injections, or devices; they buy getting better.” According to this panelist, pharma should care because digital therapeutics provide an opportunity for pharma to be a good partner with amazing technologies serving the market. “Pharma should care because digital therapeutics are proving to be as effective, if not more so, than traditional medicines,” yet another panelist attested.</p><p>With the exception of Otsuka’s approach to monitoring ingestion and some others that focus on behavior modification (i.e., coaching in non-CNS indications), many digital therapeutics are focused on the neck up (i.e., CNS), which is another reason pharma should care about DTx. “Pharma has beaten back many of the top killing diseases,” asserted Cox. But targeting CNS has provided a much different story. “We have no cures for Alzheimer’s or Parkinson’s,” he continues. A fellow panelist added, “When we think of the burden of disease as it relates to cost, digital therapeutics provide an incredible opportunity to perhaps realize success in an area where we have primarily witnessed failure.” But doing so requires biopharma, hospitals, patients, payers, and providers not only to reimagine how healthcare is delivered but also to reconsider what constitutes a therapeutic. “In areas where pharma has not delivered a therapy, it is time to look for different discovery approaches beyond the lab,” shared another panel member. However, the panelists seemed in agreement on the importance of not pigeonholing digital therapeutics to just CNS.</p><p>Here’s another reason pharma should be interested in digital therapeutics. “The method of developing digital therapeutics maps very well to how we approach discovery and development in pharma,” a different panelist asserted. “You build the basic science and mechanisms of action, run clinical trials using the same endpoints to evaluate a medication, and then go through the FDA.” On the back end, patients, payers and providers still need to be educated on the medical value, which aligns well with biopharma’s commercial engine (though sales representatives might require some new skills).</p><p>But biopharma’s success in digital therapeutics requires a mind shift. One panelist noted how many pharmas view digital therapeutics as an interesting little thing to give away that will help them sell more drugs. “We are not in the business of being the toy in the happy meal,” another panel member affirmed.</p><p>Want another reason why pharma should be interested in digital therapeutics? For starters, every new sensor creates an opportunity for intervention. But an even more exciting opportunity is the ability to take in data through the digital therapeutic itself and to then phenotype patients and personalize their treatment. With true digital therapeutics, you know at every moment how the patient is doing, allowing providers the opportunity to intervene and adjust the therapy when necessary.</p><p><strong>WHAT ARE SOME OF THE CHALLENGES FOR DIGITAL THERAPEUTICS?</strong></p><p>While digital therapeutics hold enormous promise, there remain plenty of challenges, one being reimbursement. “By going through the FDA, getting a label and an indication statement, you have a unique device identifier that facilitates CPT (current procedural terminology) coding,” a panel member explained. This fits with what insurance companies are used to. But digital therapeutics companies still need to build contracts and coverage on health economic outcomes and the medical value created. While Medicare and Medicaid are not yet reimbursing for digital therapeutics, panel members believe they will get there. “Patients with substance abuse disorder are often on Medicaid,” a panelist elaborated. If such patients aren’t treated, they tend to place a significant financial burden on the state when ending up in the ER or criminal justice system.</p><p>“How should they be priced?” asked an audience member. For example, imagine that a digital therapeutic proves to have better outcomes and better adherence than a $60,000 drug for MS. Is it worth more, the same, or less, or is it priced based on its cost of development? “We’re thinking about it a little bit more broadly,” a panel member responded. “But how such a digital therapeutic is priced should have nothing to do with whatever is charged for a pharmacological therapy.”</p><p>“How does the process work when outsourcing the clinical trial of a digital therapeutic?” asked another audience member. “It’s actually a big cultural change in how we interact with our CROs,” a panelist shared. In the traditional clinical trial model, there are delays in starting to get data, the ability to review, and give feedback. Such isn’t the case with digital therapeutics, which is certainly a positive. But execution requires more involvement from the sponsor. “You can’t just do a hand off as you would with a small molecule trial,” he elaborated. In addition, the sponsor could no longer afford to do paper-based clinical trials. Further, that company would find it needed to integrate around 12 or so technology systems in order to do clinical trials with CROs. “One site commented that they feel like Radio Shack because of all the equipment we supplied to do the trial,” he laughed. However, another panelist noted that figuring out how to do trials innovatively is top of mind for CROs (at least the 10 biggest anyway).</p><p>Another challenge is the FDA approval process. When Pear Therapeutics got the FDA’s approval for re- SET and reSET-O, it was approved as a medical device. Although the medical device review process is generally simpler than the review of drugs, there are many uncertainties due to the complexities of working with software based products, most importantly the need to make iterative software updates during the lifecycle of the product. “The FDA is currently trying to come up with a regulatory framework that works better for digital therapeutics,” a panelist stated.</p><p>A couple of final points. For every approved prescription drug, there exists a monograph. What might the monograph for a prescription digital therapeutic look like? The digital therapeutic industry is working with groups like the U.S. Pharmacopeia to envision how this should be done, along with figuring out how these should be prescribed and delivered to patients via an e-pharmacy, while also being HIPAA compliant. “There are all sorts of things that essentially have never been done before, and figuring those out is another component that makes working in digital therapeutics challenging and exciting,” a panelist finalized.</p><p><strong>CORE PRINCIPLES OF DIGITAL THERAPEUTICS</strong></p><p>According to the Digital Therapeutics Alliance (DTA), the following are core principles all digital therapeutics must adhere to:</p><ul><li>prevent, manage, or treat a medical disorder or disease</li><li>produce a medical intervention that is driven by software, and delivered via software or complementary hardware, medical device, service, or medication</li><li>incorporate design, manufacture, and quality best practices</li><li>engage end users in product development and usability processes</li><li>incorporate patient privacy and security protections</li><li>apply product deployment, management, and maintenance best practices</li><li>publish trial results inclusive of clinically meaningful outcomes in peer-reviewed journals</li><li>be reviewed and cleared or approved by regulatory bodies as required to support product claims of risk, efficacy, and intended use</li><li>make claims appropriate to clinical validation and regulatory status</li><li>collect, analyze, and apply real world evidence and product performance data</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fafc29083f8d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How close are we to platform domination in healthcare’s digital business models?]]></title>
            <link>https://medium.com/@DigitalPharma2/how-close-are-we-to-platform-domination-in-healthcares-digital-business-models-6a48ce337ecc?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/6a48ce337ecc</guid>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[dtx]]></category>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 17:41:51 GMT</pubDate>
            <atom:updated>2019-06-30T17:41:51.463Z</atom:updated>
            <content:encoded><![CDATA[<h3>Several technology firms are making attempts to dominate the digital health market. However, healthcare is very different from platform dominated markets in other sectors.</h3><p><strong><em>from </em></strong><a href="https://www.cio.com/article/3404529/how-close-are-we-to-platform-domination-in-healthcares-digital-business-models.html"><strong><em>https://www.cio.com/article/3404529/how-close-are-we-to-platform-domination-in-healthcares-digital-business-models.html</em></strong></a></p><p>Platform domination is a feature of several industry sectors, especially ones where there is a winner-takes-all outcome that is hard to replicate or compete against. Google dominates search. Amazon dominates e-commerce. Facebook dominates social media. And so on. In several industries, dominant incumbent firms have also developed their own platforms to get in front of disruptive innovation. <a href="https://www.mckinsey.com/business-functions/digital-mckinsey/our-insights/the-right-digital-platform-strategy?cid=other-eml-nsl-mip-mck&amp;hlkid=9220b0ab9c0540c99c2bbff5259ec2c0&amp;hctky=1633998&amp;hdpid=94e4dc2e-f252-4338-b4da-c30fac623f11">Research</a> by consulting firm McKinsey suggests that across sectors in developed economies, a single digital platform prevails 75% of the time, citing examples of Daimler, Nike, and Unilever.</p><p>So, how far away is healthcare from a platform-dominated digital business model ? Over the past few years, several healthcare focused cloud-based digital platforms — or health clouds — have been announced by big tech firms such as Salesforce, Microsoft, and Google. These platforms are intended to emulate the winner-take-all models that we have come to see in social media or search advertising. The McKinsey report notes that industries with lower digital maturity, such as Pharma and healthcare, see a lower level of prevalence of platforms, citing the lack of network effects, which require a large section of market participants to elect to participate in a single dominant platform, as one of the primary reasons. In a recent <a href="https://thebigunlock.com/the-big-unlock-podcast-episode-16/?utm_source=CIO&amp;utm_medium=blog&amp;utm_campaign=CIOblogJune19">conversation</a> on my podcast, John Sculley, former CEO of Apple, stated that platform technologies have revolutionized industry after industry with one big exception — healthcare. Let’s explore a few of the reasons for why that is the case.</p><h3>Most platforms fail, regardless of the sector they operate in</h3><p>A study of 250 platforms, <a href="https://hbr.org/2019/05/a-study-of-more-than-250-platforms-reveals-why-most-fail">published</a> in the Harvard Business Review, provides a sobering view of the prospects for platforms in general. For every VC-fueled Uber and Airbnb that goes for world-domination through first mover advantage and network effects, there are several that do not make it past their fifth anniversary. The reasons range from late entry to mispricing, lack of trust, and not paying attention to competition. Healthcare has historically been a low-trust economy, with payers, providers, and pharma companies in largely adversarial relationships in a zero-sum game. For platforms to succeed, market participants must share data and invest in collaborative initiatives to improve healthcare outcomes and reduce costs for the sector. The closest we have come to this ideal in healthcare is in health information exchanges (HIE), and even those have failed to gain traction due to a variety of issues.</p><p>[ Beware the <a href="https://www.cio.com/article/3404529/article/3214406/enterprise-architecture/9-warning-signs-of-bad-it-architecture.html">9 warning signs of bad IT architecture</a> and see why these <a href="https://www.cio.com/article/3404529/article/3209762/it-strategy/10-old-school-it-principles-that-still-rule.html">10 old-school IT principles still rule</a>. | <a href="http://www.cio.com/newsletters/signup.html">Sign up for CIO newsletters</a>. ]</p><h3>Users are slow to adopt digital health platforms</h3><p>For a platform economy to succeed, consumers have to use the platforms. Even telehealth platforms, seen as a transformative way to deliver healthcare, are seeing relatively low adoption rates among physicians (the American Hospital Association has <a href="https://www.aha.org/system/files/2019-02/fact-sheet-telehealth-2-4-19.pdf">documented</a> the key issues — including coverage and reimbursement by Medicare for telehealth visits). Analyst Mary Meeker’s widely read annual <a href="https://www.vox.com/recode/2019/6/11/18651010/mary-meeker-internet-trends-report-slides-2019">Internet Trends Report</a> suggests that consumers are using digital health tools primarily for basic activities such as online health information and for researching provider ratings. This suggests a gap between the billions spent by big tech firms on building platforms, and the market’s readiness for the platforms.</p><h3>It is all about the data, and who owns it</h3><p>Healthcare IT has been bedeviled by interoperability challenges, as everyone knows. For now, the custodianship of the data rests with health systems and their electronic health record (EHR) vendors. There is growing activism about handing over the ownership of the data to consumers (including a proposed CMS rule that will make it mandatory for consumers to be provided access to all their medical information), but we are still in early stages. Even if we were to get to grips with secure and seamless data exchange among participants in the health IT ecosystem, there is growing realization that the fundamental building block for driving innovation, namely a universal patient identifier, does not exist (<a href="https://www.fiercehealthcare.com/tech/house-votes-to-lift-ban-federal-funding-for-unique-patient-identifier">recent legislative action</a> could change that). Big tech firms, for their part, have to overcome a general lack of trust by consumers for sharing personal medical information on their platforms.</p><p>Notwithstanding their relative lack of digital maturity, healthcare enterprises are choosing their own pathways for adopting digital platforms. Health systems are choosing a combination of best-in-class point solutions and enterprise-scale platforms, sitting alongside their core EHR systems, to reimagine patient and caregiver experiences. Health insurance companies have firmly adopted consumerism as the focus of their digital efforts. They are providing the emerging marketplace with pricing information, health and wellness counseling, and treatment alternatives. Pharma companies are looking hard at digital therapeutics to extend brand revenues by building digital “wrappers” around their products, and to develop new drugs-as-software that cost a lot less to develop and monetize compared to traditional drug discovery models.</p><p>So far, one thing is clear. No single tech firm seems positioned to dominate healthcare in the short term. The market seems to have plenty of room for companies — incumbents, innovators, or startups — to carve out a role in the digital transformation of healthcare.</p><p>For all these reasons, platforms are only just gaining significance, and it may be early days yet. John Sculley, who is an advisor to <a href="https://www.rxadvance.com/">RxAdvance</a>, a company looking to disrupt the PBM industry with a PBM cloud offering, thinks that healthcare industry platforms are probably the greatest examples of digital health enablement. He also believes that we are going to see more and more success stories by 2020 and beyond. Perhaps the new players will demonstrate that healthcare is just as important an opportunity for platform technologies as all those other industries have been.</p><p><strong>This article is published as part of the IDG Contributor Network.</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6a48ce337ecc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[NHS to trial digital depression tool Deprexis]]></title>
            <link>https://medium.com/@DigitalPharma2/nhs-to-trial-digital-depression-tool-deprexis-294855d63c1e?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/294855d63c1e</guid>
            <category><![CDATA[digital-therapeutics]]></category>
            <category><![CDATA[dtx]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[depression]]></category>
            <category><![CDATA[cine]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 16:39:08 GMT</pubDate>
            <atom:updated>2019-06-30T16:39:08.253Z</atom:updated>
            <content:encoded><![CDATA[<p>from <a href="https://pharmaphorum.com/news/nhs-trial-digital-depression-deprexis/">https://pharmaphorum.com/news/nhs-trial-digital-depression-deprexis/</a></p><p>January 24, 2018</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/605/0*9r6jL1ljgv4hZVkV.jpg" /></figure><p><strong>NICE has recommended that the online and mobile programme Deprexis should be trialled on the NHS to treat depression.</strong></p><p>Deprexis has been developed by Gaia Healthcare and is already used in Germany where it is marketed by Servier.</p><p>Around 200 people in England could be the first to benefit from free access to this digital therapy, which will be trialled for up to two years.</p><p>People can log into the online programme at any time to complete modules of cognitive behavioural therapy, avoiding the need to attend therapist appointments in person. A therapist can see what part of the programme each person is using and they can exchange messages via a secure messaging system.</p><p>The recommendation follows a call from NICE to digital health companies to submit products to treat anxiety and depression last year.</p><p>It is part of NHS England’s Improving Access to Psychologic Therapies programme, which began in 2008 and provides access to these services for around 900,000 people each year.</p><p>Following an <a href="https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-advice/IAPT/iab-deprexis-for-publication.pdf">assessment</a>, NICE has produced its first ever digital psychological therapy briefing, concluding that Deprexis could be an effective alternative therapy for adults with depression.</p><p>Although costs in the UK have yet to be agreed, a German health economic study showed that total health costs reduced by around £970 per person when treated with Deprexis.</p><p>Another study showed total healthcare costs decreased by 32% in patients treated with Deprexis, compared with 13% in a usual care group.</p><p>However at a cost of £290 per person for Deprexis, compared with £110 per patient for a six-month course of antidepressants, the digital technology does not produce direct cost savings compared with conventional drug therapy.</p><p>But NICE said that Deprexis requires no training costs, and may be delivered using a lower grade of staff, freeing up more experienced staff to deal with patients with more serious conditions.</p><p>Deprexis is much cheaper than face-to-face individual cognitive behavioural therapy (CBT), which costs around £560.</p><p>A technical assessment said Deprexis needs to tweak the technology to bring it up to NHS standards — but a remediation plan produced by the manufacturer is acceptable.</p><p>NICE said Deprexis is well written and forms a good framework for CBT therapy to treat depression.</p><p>Gaia Healthcare is one of many digital health firms targeting depression — last year Takeda began a collaboration with UK-based Cognition Kit on an app to monitor depression.</p><p>University of Texas researchers have also developed a learning algorithm that has been trained to detect the risk of depression from brain scan data.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=294855d63c1e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Digital Therapeutics Can Break Down Barriers to Innovation to Benefit Patients]]></title>
            <link>https://medium.com/@DigitalPharma2/digital-therapeutics-can-break-down-barriers-to-innovation-to-benefit-patients-69edf823d59e?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/69edf823d59e</guid>
            <category><![CDATA[dtx]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 16:13:11 GMT</pubDate>
            <atom:updated>2019-06-30T16:14:16.910Z</atom:updated>
            <content:encoded><![CDATA[<p>Jun 19, 2019 By <a href="http://www.pharmexec.com/leo-grimaldi-md">Leo Grimaldi, MD</a>, Pharmaceutical Executive</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*AnmctuKnvz2cMwMu" /></figure><p>There is rapidly growing and sizeable evidence which shows that innovating is the most important factor in pharmaceuticals. The industry is a field which itself has developed and evolved on the basis of disruption and innovation.</p><p>Digital Therapeutics (DTx) are at the cutting edge of this new disruptive tech-led industry. They form part of the wider jigsaw of patient support and treatment services which are seeking to enhance and optimize medicine and medical treatment for those at its center — the patients.</p><p>In my former role as a Governmental advisor for the U.S. Patient Protection and Affordable Care Act — also known as Obamacare — I helped to provide insights on how new technologies could be used to improve and reform the U.S. healthcare system. These kinds of digital interventions enable better patient outreach, sign up rates, and crucially the ability to capture real-world data.</p><p>As evidence-based interventions, driven by state-of-the-art software programs, DTx contribute to the prevention, management, and treatment of a plethora of medical conditions and illnesses. By their very nature they also have the ability to capture real-world data on usage, engagement, disease progression, healthcare outcomes, and therapeutic efficiency and in doing so, can demonstrate value to patients, payors, and providers.</p><p>Integral to the successful roll out of DTx is the need for a solid digital therapy management platform. Such a platform integrates the tools and support needed for the holistic treatment of the patient’s condition.</p><p>These platforms can help to empower patient self-management, enhance clinical care coordination, and capture the real-world data.</p><p>By integrating behavioral science into these platforms, we can also get a better understanding of both the needs of the patient and of their clinicians, when particular treatments are prescribed.</p><p>I believe that the pharmaceutical industry is now slowly getting up to speed on digital interventions. What, in the past, was a software solution developed by cutting-edge start-ups, has now become the core focus of attention of much larger industry players who are realizing the importance, both from a financial and public health perspective, of producing better outcomes for patients.</p><p>The reality is that life science companies require real-world data, and relevant statistics that show the value delivered to the healthcare system beyond what can be seen through clinical trials alone. As a result, there has been an increased focus on digital technologies that can generate data to demonstrate value. For the pharmaceutical industry this has meant a shift from seeing digitally-enabled interventions from a ‘nice to have’ to a ‘must have.’</p><h3>Challenges</h3><p>Until recently, there has been a disconnect between start-ups, pharmaceutical companies, and payors. Going forward, partners working together on DTx will need to agree on their definition of, and the opportunities in DTx.</p><p>It is crucial to put the patient at the center of any solution that is provided — imagine yourself as a patient with hypertension who is taking four different drugs to manage your condition.</p><p>Assuming each of the drugs is supported by an app, patients will not want to be using four different apps.</p><p>For DTx to work at scale, and to gain broad adoption by patients, they need a solution that will combine the various elements of their treatment to support them to effectively manage their condition and achieve the best possible healthcare outcome.</p><h3>Crystal ball gazing</h3><p>One thing is certain, we will continue to see regulatory bodies and industry associations adapt and define the evolving DTx space for some time to come.</p><p>Recent examples include the U.S. Food and Drug Administration’s Digital Health Innovation Action Plan, the Digital Therapeutics Alliance, and the Digital Medicine Society.</p><p><strong>There is now a real opportunity for pharma companies to think about breaking down the historical barriers between them to collaborate in designing digital solutions that put the patient, their journey, and their experience at the center. It is here that digital therapy management platforms can play the most important role.</strong></p><p><strong><em>Leo Grimaldi, MD</em></strong><em>, is </em><a href="https://www.s3connectedhealth.com/"><em>S3 Connected Health </em></a><em>director of digital therapy management and patient support services.<br></em><a href="http://www.pharmexec.com/digital-therapeutics-can-break-down-barriers-innovation-benefit-patients"><em>http://www.pharmexec.com/digital-therapeutics-can-break-down-barriers-innovation-benefit-patients</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=69edf823d59e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[ARTIFICIAL INTELLIGENCE SOFTWARE: FDA NEWS]]></title>
            <link>https://medium.com/@DigitalPharma2/artificial-intelligence-software-fda-news-68f346d2146e?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/68f346d2146e</guid>
            <category><![CDATA[fda]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 16:01:57 GMT</pubDate>
            <atom:updated>2019-06-30T16:01:57.556Z</atom:updated>
            <content:encoded><![CDATA[<p>from <a href="https://www.portolano.it/en/pcc_newsletters_life/artificial-intelligence-software-fda-news/">https://www.portolano.it/en/pcc_newsletters_life/artificial-intelligence-software-fda-news/</a></p><p>On April 2, 2019, a discussion paper describing a proposal for a regulatory framework for modifications to Artificial Intelligence-based medical devices that are already on the market, was published by the Food and Drug Administration (FDA), in view of the future formulation of guidelines that relate to this issue.</p><p>In the American regulatory framework, artificial intelligence (AI) and machine learning-(ML)based technologies, that are intended to be used for a single, or more, medical purposes (i.e., to treat, detect, cure, reduce or prevent diseases) are included in the category of software as a medical device (SaMD). It should be noticed that, according to the definition given by the International Medical Device Regulators’ Forum, SaMD are those software packages that are intended for use for one or more medical purposes, and that perform these purposes without being part of a medical hardware device. Specifically, AI/ML-based SaMD differ from other SaMDs due to their ability to learn from real-world feedback and, therefore, can improve their performance.</p><p>These technologies have an enormous potential that is related to the development of healthcare, i.e., enabling the possibility for early and more detailed diagnosis.</p><p><strong>FDA discussion paper</strong></p><p>From a regulatory perspective, there is a need to prepare an adequate regulatory framework in order to support the constant learning and updating of the algorithms that are the basis of the software and, at the same time, to ensure appropriate levels of safety and effectiveness over the entire device’s lifecycle. With this purpose, on April 2, 2019, the FDA published a discussion paper on a proposal for a regulatory framework for modifications to AI/ML-based software.</p><p><strong>The application of the total product lifecycle regulatory approach to AI/ML based SaMDs</strong></p><p>The discussion paper’s legislative approach considers the whole lifecycle of AI/ML based medical devices (Total product lifecycle regulatory approach), with the purpose of ensuring the products’ safety and quality from their premarket development to the necessary after sales services. It is a similar approach to that envisaged by the software pre-certification program, published by the FDA, in January 2019. This regulation seems to be applicable only to those AI/ML-based SaMDs that require a premarket submission.</p><p>In order to achieve this purpose, the software manufacturer has to establish quality and good practice standards inside his structure for the entire lifecycle of the product (Quality systems and good machine learning practices — Gmlp), in order to achieve the clinical validation of the software.</p><p><strong>Predetermined software change control plan</strong></p><p>Secondly, a verification of safety and effectiveness requirements during the premarket phase of the product is requested. For this purpose, the discussion paper has proposed a pre-determined change control plan which can be used during the initial premarket request for an AI/ML based SaMD. The predetermined change control plan should include the types of modifications that are to be expected as a result of the constant updating and retraining of such software (SaMD pre-specifications) and the associated methodology should be used in order to implement those changes in a controlled manner, while managing risks to patients (Algorithm Change Protocol).</p><p><strong>Regulation of AI/ML-based SaMD modifications after they are put on the market</strong></p><p>Possible modifications, due to the software’s adaptation to the real-world, are considered to be changes to SaMD when it has already received the FDA’s authorization of the premarket submission. The FDA discussion paper requires manufacturers to implement these changes, taking into account the risk for the patients.</p><p>In the light of the regulatory framework described above, if the changes that are made fall within the limits of the modifications already approved in the pre-determined change control plan, the software manufacturer should simply document the modification made on the software. Otherwise, manufacturers will have to submit a new market application to the FDA.</p><p><strong>Manufacturers’ transparency and monitoring duties</strong></p><p>Finally, the manufacturer should commit to the principles of transparency and real-word performance monitoring, providing reports on the real performances of the devices during their post-market phase, ensuring that the labelling describes, in a suitable and detailed manner, those modifications that have been made on the software.</p><p>In conclusion, the FDA discussion paper affirms that the new regulatory approach should provide for a reasonable assurance of safety and effectiveness in relation to AI/ML-based SaMDs during the entire software lifecycle. Furthermore, this regulatory approach would enable both the FDA and the manufacturers to test and monitor these devices from the pre- to the post-market phase.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=68f346d2146e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Forming new evidence research collaborations around digital health interventions]]></title>
            <link>https://medium.com/@DigitalPharma2/forming-new-evidence-research-collaborations-around-digital-health-interventions-6b74d6e32bbf?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/6b74d6e32bbf</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[digital]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 30 Jun 2019 15:55:55 GMT</pubDate>
            <atom:updated>2019-06-30T15:55:55.413Z</atom:updated>
            <content:encoded><![CDATA[<p>from <a href="https://digitalhealth.london/events/research-collaborations-digital-health-interventions/">https://digitalhealth.london/events/research-collaborations-digital-health-interventions/</a></p><p><em>Are you a researcher interested in, or already working with, digital health tools? Are you interested in forming new collaborations to carry out research into these tools and interventions?</em></p><p>We’d love to invite you to this event exploring new opportunities to generate evidence around digital health, and highlighting examples of where this type of ground-breaking work is already underway.</p><p>With an increasing number of digital health innovations available to patients and healthcare staff, evidence generation is becoming ever more important for digital health companies. NICE has recently published its first Evidence Standards Framework for Digital Health Technologies, and with this, even more work is happening in this space. To work with the NHS, digital health innovators must ensure they are meeting minimum evidence standards, and academics are increasingly working to better define the methodologies used to evaluate these innovations and their impact.</p><p>The event will bring together digital health companies and academics / researchers with an interest in digital health evidence generation and showcase some of the examples of work already being done through the DigitalHealth.London “Evidence Generator.” We want to encourage the formation of new research collaborations to generate the evidence needed for the NHS to consider adopting a digital health tool.</p><p>We will facilitate discussions around the barriers companies face in generating evidence, and take a look into the future, asking: “What will the methodologies look like when it comes to evaluating digital health innovations?”</p><p>We want attendees to leave feeling inspired and empowered to form new research relationships with digital health companies.</p><p>About the DigitalHealth.London Evidence Generator</p><p>The project was set up in 2018 to help create new research collaborations for evidence generation between SMEs and academics and is still in the early stages of development. This event is an opportunity to review progress and support the creation of new research collaborations.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6b74d6e32bbf" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Activating Digital Opinion Leaders]]></title>
            <link>https://medium.com/@DigitalPharma2/activating-digital-opinion-leaders-3b671ec262e3?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/3b671ec262e3</guid>
            <category><![CDATA[social-media]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 23 Jul 2017 10:43:14 GMT</pubDate>
            <atom:updated>2017-07-23T10:43:14.634Z</atom:updated>
            <content:encoded><![CDATA[<p><strong><em>How the Internet, social media and mobile channels are changing the key opinion leader and advocate environment</em></strong></p><p>A guide for pharmaceutical communicators and marketers by<br>Daniel Ghinn<em><br></em>© 2016 CREATION Interactive Ltd</p><p><strong>Introduction</strong></p><p>Back in 2012, I presented a session at KOL &amp; MSL Best Practice conference in Basel, Switzerland. The conference focused on pharmaceutical companies’ work with Key Opinion Leaders (KOLs) and the role of Medical Science Liaisons, and I had been invited to speak on how new channels like the Internet, social media and mobile are changing the KOL environment.</p><p>In my session I introduced the concept of ‘Digital Opinion Leaders’ for pharmaceutical companies, arguing that in today’s digital environment there are two key concepts that affect the potential role of opinion leaders:</p><p>1. In the digital world, a pharmaceutical company’s stakeholders are influenced by a surprising range of individuals who might not previously have been considered ‘Opinion Leaders’</p><p>2. In identifying those healthcare professionals who influence their peers, the role of digital engagement is an increasingly important aspect of their influence These concepts should not detract from ‘traditional’ KOL activity but provide an added dimension to pharmaceutical companies’ engagement planning.</p><p>I presented CREATION’s method of activating Digital Opinion Leaders in three steps: Identify, Engage &amp; Activate.</p><p>At first glance, this looks much like the model used in traditional KOL activity. The difference in the digital world, I illustrated, is that each of these steps requires a paradigm shift in order to be effective.</p><p>This white paper has been written based upon what I presented in Basel, as well as learning since, and includes more in-depth discussion and recommendations for those in pharmaceutical companies who wish to activate advocates in the digital era.</p><p><em>[continue]</em></p><p><strong><em>You may read the full White paper at </em></strong><a href="http://www.creation.co/"><strong><em>www.creation.com</em></strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3b671ec262e3" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Medical Affairs — The Rising Star of Pharma Communications]]></title>
            <link>https://medium.com/@DigitalPharma2/medical-affairs-the-rising-star-of-pharma-communications-f35f29af4297?source=rss-88a09b2175ab------2</link>
            <guid isPermaLink="false">https://medium.com/p/f35f29af4297</guid>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[DigitalPharma2.0]]></dc:creator>
            <pubDate>Sun, 23 Jul 2017 07:31:22 GMT</pubDate>
            <atom:updated>2017-07-23T07:31:22.154Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/700/0*s_-CHSA5euIbGWhs.jpg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/200/0*TajjxPiaDi2i1ev7.jpg" /></figure><p><a href="https://www.linkedin.com/in/phanishchandra"><strong>Phanish Chandra</strong></a><strong><br>CEO &amp; Founder at Docplexus.in <br></strong>Visit <a href="http://docplexus-insights.com/">Docplexus Blog </a>for more insights!</p><p>Technological advances, regulatory pressures, rising litigations and changing consumer needs are forcing pharma leaders to revisit their traditional practices leading to a paradigm shift in various functional roles and responsibilities. With the industry’s <strong>focus shifting from products to outcomes</strong>, the objectives of medical affairs (MA) function are also undergoing a drastic change.</p><blockquote><strong>The MA team no longer plays a behind-the-scenes, supportive role. It has emerged as the driver of all external stakeholder engagement</strong>.</blockquote><p>Important areas of influence under the purview of MA include medical science liaison (MSL) programs, health economics, investigator-initiated trials, thought-leadership development, medical publications, compliance and regulation, medical grants, health economics, and much more. In fact, leading organizations now consider <strong>MA at par with R&amp;D and commercial functions</strong>, and are involving its staff into more strategic, customer-facing activities.</p><p><strong>Why Is Medical Affairs Pharma’s New Epicenter of Stakeholder Engagement?</strong></p><ul><li><strong>Shift from Generics to Discovery of New Molecules</strong> — Although India has traditionally been the hub of generics, the past few years have witnessed several domestic and multinational players focusing their R&amp;D efforts on new molecule development, handing over the post-launch activities to MA team. The future is expected to bring more <strong>specialized, targeted treatment</strong> requiring partial replacement of the current incentive-based engagement model of sales reps by value-added, scientific interactions initiated through the MA staff.</li><li><strong>Changing Key Opinion Leader (KOL) Expectations</strong> –Today’s doctors are operating in an increasingly challenging environment characterized by a rise in medico-legal cases and drug-resistant bacteria, increasingly stringent regulations, availability of new channels of information, etc. MA teams are well-equipped to help them <strong>navigate through these complexities</strong>. Moreover, physicians are increasingly demanding their engagement with pharma to deliver<strong> better value through a more intellectual exchange</strong> of information. MSL are better placed than sales reps to convey the science behind the product.</li><li><strong>More Complex, Specialized Therapies</strong> — Technological innovations are making diagnostic tools more sophisticated. New age drugs are increasingly complex, having multiple indications. Specialized treatment of rare diseases is steadily gaining ground. <strong>Research by Bain &amp; Co. reveals that today’s doctors, especially the younger ones, rely more on academic journals, CMEs, KOLs and other scientific sources of information</strong>. The ability of the MA team to offer in-depth knowledge on specialty medicine builds pharma’s credibility with physicians.</li><li><strong>Diverse Stakeholders</strong> — Apart from physicians, pharma companies now have to convince a new set of stakeholders like patient advocacy groups, payers and healthcare authorities, of the effectiveness of their therapy. The evidence/information demanded by each of these stakeholders is varied. <strong>The MA department is capable of meeting diverse informational requirements of various entities</strong>. Often, stakeholder engagement goes beyond the product to assume a much broader scope including educational initiatives, disease management programs and other activities that make possible delivery of the best possible care. By engaging well with external stakeholders, MA can tap the best opportunities, gain insights into influencers’ opinions and contribute to the formation of the most effective strategies.</li><li><strong>Emergence of Big Data</strong> — MA professionals, with an exhaustive understanding of the disease as well as products, are uniquely positioned to sieve through the vast amounts of data generated from various sources to offer meaningful insights for the development of better therapies. Data Analytics also helps them effectively <strong>identify and segment KOLs</strong> and devise targeted engagement strategies based on individual interests and inclinations. They can now provide intelligence on the medical market for use in clinical trial programs.</li><li><strong>Rising Focus on Real World Evidence</strong> — MA personnel are uniquely positioned to collate and analyze real-world evidence i.e. observational data drawn from patient claims, electronic health records, social media behavior and patient registries. An expert MA team can connect scientific and clinical findings to actual patient outcomes. This adds value to each stage of the drug’s development.</li><li><strong>Health Economics and Outcomes Research (HEOR) — </strong>MA participate in research to determine most effective and economical treatment options and present the findings to external stakeholders such as KOLs. HEOR is one of the key focus areas of KOLs as it affects the duration of hospitalization, cost of care and other important parameters.</li><li><strong>Minimal Impact of Regulatory Changes</strong> — The proposed UCPMP Act will bring stringent restrictions on sales representatives’ engagement practices. In this challenging environment, conducting <strong>convincing, real world discussions</strong> <strong>with physicians will become more daunting, calling for a</strong> <strong>more senior, knowledgeable person</strong> at the helm of affairs. Moreover, since the interactions between MA and KOLs have always focused on a scientific exchange as the key deliverable, they will stay uncompromised in the event of more restrictive regulations. Additionally, being well-versed with the recent regulatory environment, the MA department is better-positioned to ensure compliance, transparency and trust across stakeholders.</li><li><strong>Need for Better ROI in Tough Operative Environment </strong>— The MA team has a large role to play in maximizing returns by conveying vital information about the market feasibility of a new molecule, gathered during its interactions with various external stakeholders, right at the onset of the drug development process. Over time, such feedback, creates a strong competitive advantage as only the most effective clinical programs are undertaken.</li></ul><p>The onus of creating an environment that encourages the MA team to successfully execute this new, multi-faceted role, lies on the top leadership. Following are the areas that need immediate evaluation by the C-Suite:</p><p><strong>The 5Rs of Deriving Strategic Value from Medical Affairs</strong></p><ul><li><strong>Revisit Communication Channels — </strong>Multichannel engagement will enable optimal access to KOLs and other external stakeholders. Digital technology, when effectively harnessed, can help <strong>uncover every missed data point and strengthen competitive positioning</strong> by providing intelligence on rivals’ moves. A communications strategy that leaves out social media platforms is a missed opportunity. Internally too, MA department needs to be given <strong>access to all necessary information</strong> so as to avoid a situation where the company pays a heavy price (product recalls, damaged reputation and financial losses) as a result of negative patient outcomes.</li><li><strong>Reskill</strong> <strong>Workforce — </strong>Often, MSLs stress on a specific disease. However, they need to develop a broader perspective of the healthcare system and the impact of that particular disease or therapeutic area on the organization as a whole. In future<strong>, a perfect MA professional would possess the right mix of deep scientific understanding, strategic mindset and business acumen</strong>. The team should be trained in the best stakeholder engagement practices along with an in-depth knowledge of the regulatory environment as well as the HEOR data. It is crucial to involve the legal and compliance departments in the development of the training program.</li><li><strong>Restaff and Redefine Job Roles</strong> — The erstwhile office-based MA teams are now entrusted with additional responsibilities that have them spending more time with their external stakeholders rather than the internal ones. This calls for <strong>new job descriptions</strong> that cover attending medical conferences, writing in medical publications, and delivering scientific presentations, among others. Adding to the existing staff should also be considered to ensure all responsibilities are successfully executed.</li><li><strong>Reaffirm Benchmarks — </strong>Standards of operations and assessment of outcomes lie at the core of an efficient organization. Valid benchmarks need to be established and communicated to all concerned. Continuous and comprehensive <strong>measurement of performance indicators</strong> like the no. of attendees for medical conferences, no. of medical articles published, no. and stature of KOLs engaged, quality of scientific presentations made, etc. will ensure optimal outcomes.</li><li><strong>Reallocate Budget — </strong>Widening of the MA function to include new responsibilities will require more resources. Budgetary revisions and reallocation are imperative if MA has to be effective in its new role.</li></ul><p>In future, exchanges between MA and external stakeholders, particularly KOLs, will determine the level of integrity, authenticity and comprehensiveness of scientific information provided by pharma and imprint the company’s image on the outside world. It is imperative that MA is given the attention and strategic positioning it rightly deserves.</p><p>Visit <a href="http://docplexus-insights.com/">Docplexus Blog </a>for more insights!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f35f29af4297" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>